Compare
Innoviva vs Johnson & Johnson (INVA vs JNJ)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Innoviva (INVA) returned +4.8% and Johnson & Johnson (JNJ) +48.5%; so far this year the figures are -4.5% and +33.5%.
Johnson & Johnson is the larger company by market value, about 488.9 times the size of Innoviva.
On trailing earnings, INVA trades at 9.6 times and JNJ at 41.9 times.
Revenue grew +12.8% at INVA and +7.8% at JNJ over the last year.
INVA pays no dividend. JNJ yields 1.91%.
Data as of the latest close. Not investment advice.
Relative performance
| INVA | JNJ | |
|---|---|---|
| Price | $19.10 | $276.22 |
| 1-day | -0.73% | +1.43% |
| YTD | -4.45% | +33.47% |
| 1 year | +4.77% | +48.51% |
| 3 years | +53.78% | +85.77% |
| Market cap | $1.4B | $665.0B |
| P/E | 9.6 | 41.9 |
| P/S | 3.10 | 6.69 |
| P/B | 1.19 | 8.16 |
| Revenue growth | +12.80% | +7.80% |
| EPS growth | +40.80% | -36.40% |
| Gross margin % | 74.5 | 67.6 |
| Net margin % | 44.1 | 16.2 |
| ROE % | 17.0 | 19.7 |
| Debt / equity | 0.23 | 0.55 |
| FCF yield % | 13.4 | 3.1 |
| Dividend yield % | — | 1.91 |
| Beta | 0.28 | -0.09 |
| RSI (14) | 31.2 | 59.4 |
| Technical rating |